Shilpa Medicare Ltd

Shilpa Medicare Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Shilpa Medicare Ltd

₹ 538 2.33%
05 Jun - close price
vbshilpa.com BSE: 530549 NSE: SHILPAMED
About

Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.[1]

Key Points

Established Business of API & Formulations
The Co. is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology. It supplies more than 30 oncology APIs for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. [1] The API facilities are approved by several national and international regulatory bodies like USFDA, EU, Cofepris- Mexico, PMDA-Japan, Korean FDA, TPD Canada & TGA-Australia. [2]

It has about 19 API & intermediate manufacturing blocks with segregation of Oncology and Non-Oncology manufacturing facilities. [3]

It has vertically integrated the formulations segment. It manufactures Injectable Dosage Forms, Oral Solid Dosage Forms, Oral Disintegrating Films, and various prescription and OTX products for the overseas and Indian markets. [4]

Website BSE NSE
  • Market Cap ₹ 10,523 Cr.
  • Current Price ₹ 538
  • High / Low ₹ 543 / 260
  • Stock P/E 91.1
  • Book Value ₹ 139
  • Dividend Yield 0.09 %
  • ROCE 4.91 %
  • ROE 4.27 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Stock is trading at 3.88 times its book value
  • Tax rate seems low
  • Company has a low return on equity of 3.36% over last 3 years.
  • Earnings include an other income of Rs.57.6 Cr.
  • Promoter holding has decreased over last 3 years: -9.88%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
66 38 75 64 59 96 130 125 126 92 135 166 201
80 68 67 67 80 73 87 103 88 75 96 135 141
Operating Profit -14 -31 7 -3 -21 23 43 22 38 17 39 31 60
OPM % -21% -81% 10% -5% -36% 24% 33% 18% 30% 18% 29% 19% 30%
5 14 23 22 19 31 20 16 -34 13 15 9 35
Interest 7 7 5 3 3 2 1 1 2 2 2 3 3
Depreciation 12 12 13 12 12 12 12 12 12 13 13 14 14
Profit before tax -27 -35 12 4 -17 40 50 25 -10 15 39 24 78
Tax % 7% 8% 45% 31% 10% 31% 40% 37% -43% -40% 21% 33% 9%
-29 -38 7 3 -18 28 30 16 -6 21 31 16 71
EPS in Rs -1.67 -2.19 0.38 0.16 -1.06 1.43 1.53 0.80 -0.29 1.06 1.58 0.81 3.63
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
565 676 734 741 664 806 257 357 248 310 476 597
429 511 551 562 487 561 223 335 291 284 353 441
Operating Profit 137 164 183 179 177 245 34 22 -44 26 123 156
OPM % 24% 24% 25% 24% 27% 30% 13% 6% -18% 8% 26% 26%
5 9 15 23 21 32 204 170 159 79 39 58
Interest 4 3 3 2 3 4 6 9 21 17 7 10
Depreciation 19 21 27 33 34 35 22 35 47 50 49 55
Profit before tax 119 149 169 167 162 238 210 148 48 38 107 148
Tax % 29% 24% 24% 20% 23% 19% 12% 5% -18% 29% 35% 10%
84 113 127 133 124 194 184 141 57 27 70 133
EPS in Rs 5.45 7.32 7.95 8.17 7.61 11.88 11.31 8.12 3.29 1.55 3.57 6.80
Dividend Payout % 5% 4% 4% 4% 7% 5% 5% 7% 0% 0% 14% 0%
Compounded Sales Growth
10 Years: -1%
5 Years: 18%
3 Years: 34%
TTM: 25%
Compounded Profit Growth
10 Years: 0%
5 Years: -3%
3 Years: 17%
TTM: 22%
Stock Price CAGR
10 Years: 9%
5 Years: 13%
3 Years: 65%
1 Year: 18%
Return on Equity
10 Years: 7%
5 Years: 4%
3 Years: 3%
Last Year: 4%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 8 8 8 8 8 8 8 9 9 9 10 20
Reserves 555 657 1,022 1,149 1,273 1,445 1,630 2,057 2,109 2,134 2,691 2,694
87 86 237 186 186 380 655 195 290 144 108 132
132 178 224 204 201 188 225 635 112 132 198 183
Total Liabilities 783 929 1,490 1,547 1,668 2,021 2,517 2,896 2,519 2,419 3,007 3,029
280 350 449 489 511 517 641 566 609 586 570 899
CWIP 88 89 137 201 401 373 482 293 226 228 281 37
Investments 140 154 326 231 89 93 219 238 244 246 1,280 1,223
275 336 579 627 667 1,038 1,175 1,800 1,439 1,358 876 870
Total Assets 783 929 1,490 1,547 1,668 2,021 2,517 2,896 2,519 2,419 3,007 3,029

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
67 120 50 54 164 130 70 174 2 10 -19 60
-139 -101 -275 -13 -215 -295 -238 -379 -95 155 -431 -67
74 -15 315 -61 8 170 256 97 88 -163 450 14
Net Cash Flow 2 4 91 -20 -42 5 87 -108 -5 2 -0 7
Free Cash Flow -9 26 -61 -72 -108 -204 -196 0 -56 -46 -76 -67
CFO/OP 68% 92% 46% 53% 113% 70% 336% 954% -24% 64% -1% 52%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 45 60 83 107 100 103 310 105 165 170 146 136
Inventory Days 142 126 173 174 275 283 1,847 472 420 458 450 285
Days Payable 77 99 103 103 111 105 351 111 142 215 67 138
Cash Conversion Cycle 110 87 153 179 264 281 1,806 466 443 412 529 282
Working Capital Days 37 33 83 103 110 235 271 135 573 188 189 146
ROCE % 21% 21% 16% 12% 11% 15% 2% 1% -1% 3% 6% 5%

Insights

In beta
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
API Reactor Capacity (Unit I & II)
KL

Log in to view insights

Please log in to see hidden values.

Login
Biologics Fermentation Capacity
KL
Cumulative DMF Filings (Major Regulatory Authorities)
Number
Adjusted ROCE (Excl. Biologics/NBE Investments)
%
R&D Personnel
Number
Formulation Product Portfolio/Pipeline (US and EU)
Number
Backward Integration Percentage
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
50.01% 50.01% 50.01% 50.01% 44.39% 44.33% 44.23% 44.23% 44.23% 44.23% 40.13% 40.13%
10.26% 8.60% 8.52% 5.63% 9.08% 9.59% 9.90% 10.97% 11.19% 10.92% 10.97% 11.07%
0.37% 0.41% 0.06% 1.65% 7.61% 8.18% 8.27% 7.55% 7.46% 7.67% 8.34% 8.58%
39.36% 40.98% 41.41% 42.71% 38.91% 37.90% 37.59% 37.25% 37.10% 37.18% 40.56% 40.21%
No. of Shareholders 50,43444,09443,63046,04641,07242,78449,03450,10848,63652,06553,79953,410

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls